[1] CRUZ-JENTOFT AJ, BAHAT G, BAUER J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1): 16-31.
[2] 陈琳,吴钰祥,杨隽,等.运动干预肌少症与肌-脑-肠环路的研究进展[J].武汉体育学院学报,2021,55(3):70-74.
[3] 段玉梅,范彩丽,王安素,等.骨性关节炎与肌少症的相关性及其运动营养干预研究进展[J].护理研究,2022,36(1):105-109.
[4] IZZO A, MASSIMINO E, RICCARDI G, et al. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients. 2021;13(1):183.
[5] 杨则宜,焦颖.老年肌肉减少症的认知和研究最新进展[J].北京体育大学学报,2019,42(9): 10-18.
[6] 肌少症共识[J].中华骨质疏松和骨矿盐疾病杂志,2016,9(3):215-227.
[7] 卢冬磊,冯展鹏,曹立全,等.老年肌少症的运动干预[J].中国组织工程研究,2024,28(35): 5723-5731.
[8] 田小丽.乌鲁木齐市中老年人群膳食质量与肌肉减少症关联的病例对照研究[D].乌鲁木齐:新疆医科大学,2020.
[9] 许一宁,赵洁,黄月娇,等.膝骨关节炎患者恐动症的现状及其影响因素分析[J].现代临床护理,2022,21(2):14-18.
[10] CHEN LK, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300-307.e2.
[11] 高天,张勇,张丹,等.骨骼肌干细胞及其微环境调控肌少症的研究进展[J].中国医学科学院学报,2024,46(6):958-964.
[12] LIU M, WANG J, HAN Y, et al. Comprehensive landscapes of the causal network between immunity and sarcopenia. Front Immunol. 2024; 15:1443885.
[13] ZHOU J, LIU Y, WU J. Association between immune cells, inflammatory cytokines, and sarcopenia: Insights from a Mendelian randomization analysis. Arch Gerontol Geriatr. 2025;128:105560.
[14] YIN P, CHEN M, RAO M, et al. Deciphering Immune Landscape Remodeling Unravels the Underlying Mechanism for Synchronized Muscle and Bone Aging. Adv Sci (Weinh). 2024;11(5):e2304084.
[15] VILLEGAS JA, VAN WASSENHOVE J, MERRHEIM J, et al. Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis. J Neuroinflammation. 2023;20(1):9.
[16] GREIGERT H, RAMON A, GENET C, et al. Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritis. J Autoimmun. 2024;142:103151.
[17] 刘晏东,邓强,张彦军,等.调节性T细胞/Th17细胞平衡在肌骨衰减及重建中作用的研究进展[J].细胞与分子免疫学杂志,2024,40(10): 948-953.
[18] 董云峰,王海,邱俊强.不同类型细胞调控骨骼肌修复再生研究进展[J].中国运动医学杂志, 2024,43(7):563-571.
[19] HUANG SW, XU T, ZHANG CT, et al. Relationship of Peripheral Lymphocyte Subsets and Skeletal Muscle Mass Index in Sarcopenia: A Cross-Sectional Study. J Nutr Health Aging. 2020;24(3): 325-329.
[20] HEO SJ, PARK S, JEE YS. Navigating the nexus among thigh volume, myokine, and immunocytes in older adults with sarcopenia: A retrospective analysis in a male cohort. Arch Gerontol Geriatr. 2024;117:105273.
[21] KEILICH SR, CADAR AN, AHERN DT, et al. Altered T cell infiltration and enrichment of leukocyte regulating pathways within aged skeletal muscle are associated impaired muscle function following influenza infection. Geroscience. 2023;45(2): 1197-1213.
[22] JIA Q, HAO RJ, LU XJ, et al. Identification of hub biomarkers and immune cell infiltration characteristics of polymyositis by bioinformatics analysis. Front Immunol. 2022;13:1002500.
[23] WILFAHRT D, DELGOFFE GM. Metabolic waypoints during T cell differentiation. Nat Immunol. 2024; 25(2):206-217.
[24] LIU D, WANG S, LIU S, et al. Frontiers in sarcopenia: Advancements in diagnostics, molecular mechanisms, and therapeutic strategies. Mol Aspects Med. 2024;97:101270.
[25] ZHU J, PAUL WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557-1569.
[26] YIN KF, CHEN T, GU XJ, et al. Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for sarcopenia. J Cachexia Sarcopenia Muscle. 2024;15(4):1324-1334.
[27] JIANG W, ZHAN W, ZHOU L, et al. Potential therapeutic targets for sarcopenia identified by Mendelian randomisation. Age Ageing. 2023; 52(2):afad024.
[28] WEN S, XU S, ZONG X, et al. Association Analysis of the Circulating Proteome With Sarcopenia-Related Traits Reveals Potential Drug Targets for Sarcopenia. J Cachexia Sarcopenia Muscle. 2025;16(1):e13720.
[29] LUO J, LI J, WANG W, et al. Identifying the Shared Metabolite Biomarkers and Potential Intervention Targets for Multiple Sarcopenia-Related Phenotypes. Int J Mol Sci. 2024;25(22):12310.
[30] WU J, CHEN X, LI R, et al. Identifying genetic determinants of sarcopenia-related traits: a Mendelian randomization study of druggable genes. Metabolism. 2024;160:155994.
[31] DAVIES NM, HOLMES MV, DAVEY SMITH G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.
[32] NELSON MR, TIPNEY H, PAINTER JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856-860.
[33] ACKERMANN M, SIKORA-WOHLFELD W, BEYER A. Impact of natural genetic variation on gene expression dynamics. PLoS Genet. 2013;9(6): e1003514.
[34] QI C, BERG M, CHU X, et al. Cell-type eQTL deconvolution of bronchial epithelium through integration of single-cell and bulk RNA-seq. Allergy. 2022;77(12):3663-3666.
[35] SOSKIC B, CANO-GAMEZ E, SMYTH DJ, et al. Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation. Nat Genet. 2022;54(6):817-826.
[36] WU X, YING H, YANG Q, et al. Transcriptome-wide Mendelian randomization during CD4+ T cell activation reveals immune-related drug targets for cardiometabolic diseases. Nat Commun. 2024; 15(1):9302.
[37] SCHMIEDEL BJ, SINGH D, MADRIGAL A, et al. Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell. 2018;175(6): 1701-1715.e16.
[38] VÕSA U, CLARINGBOULD A, WESTRA HJ, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300-1310.
[39] GTEX CONSORTIUM; LABORATORY, DATA ANALYSIS &COORDINATING CENTER (LDACC)—ANALYSIS WORKING GROUP; STATISTICAL METHODS GROUPS—ANALYSIS WORKING GROUP, et al. Genetic effects on gene expression across human tissues. Nature. 2017;550(7675):204-213.
[40] WANG Q, ZHAO X, WANG S, et al. Sarcopenia and immune-mediated inflammatory diseases: Evaluating causality and exploring therapeutic targets for sarcopenia through Mendelian randomization. Int Immunopharmacol. 2025;144: 113687.
[41] PEI YF, LIU YZ, YANG XL, et al. The genetic architecture of appendicular lean mass characterized by association analysis in the UK Biobank study. Commun Biol. 2020;3(1):608.
[42] JONES G, TRAJANOSKA K, SANTANASTO AJ, et al. Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. Nat Commun. 2021;12(1):654.
[43] MEMBREZ M, MIGLIAVACCA E, CHRISTEN S, et al. Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia. Nat Metab. 2024;6(3): 433-447.
[44] 1000 GENOMES PROJECT CONSORTIUM; ABECASIS GR, AUTON A, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65.
[45] BOWDEN J, DEL GRECO MF, MINELLI C, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol. 2019;48(3):728-742.
[46] BURGESS S, DAVEY SMITH G, DAVIES NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2023;4:186.
[47] DAVEY SMITH G, HEMANI G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.
[48] ZHU Z, ZHANG F, HU H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481-487.
[49] WU Y, ZENG J, ZHANG F, et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nat Commun. 2018;9(1):918.
[50] GIAMBARTOLOMEI C, VUKCEVIC D, SCHADT EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383.
[51] FOLEY CN, STALEY JR, BREEN PG, et al. A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. Nat Commun. 2021;12(1):764.
[52] NOVIKOVA G, KAPOOR M, TCW J, et al. Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun. 2021;12(1):1610.
[53] GIANNOS P, PROKOPIDIS K, RALEIGH SM, et al. Altered mitochondrial microenvironment at the spotlight of musculoskeletal aging and Alzheimer’s disease. Sci Rep. 2022;12(1):11290.
[54] BÉNIT P, SLAMA A, CARTAULT F, et al. Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome. J Med Genet. 2004;41(1):14-17.
[55] HAACK TB, HABERBERGER B, FRISCH EM, et al. Molecular diagnosis in mitochondrial complex I deficiency using exome sequencing. J Med Genet. 2012;49(4):277-283.
[56] DISTELMAIER F, KOOPMAN WJ, VAN DEN HEUVEL LP, et al. Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. Brain. 2009;132(Pt 4):833-842.
[57] PEREIRA CV, PERALTA S, ARGUELLO T, et al. Myopathy reversion in mice after restauration of mitochondrial complex I. EMBO Mol Med. 2020;12(2):e10674.
[58] VINOTHKUMAR KR, ZHU J, HIRST J. Architecture of mammalian respiratory complex I. Nature. 2014;515(7525):80-84.
[59] DIETEREN CE, WILLEMS PH, VOGEL RO, et al. Subunits of mitochondrial complex I exist as part of matrix- and membrane-associated subcomplexes in living cells. J Biol Chem. 2008; 283(50):34753-34761.
[60] CHANG CH, CURTIS JD, MAGGI LB JR, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6): 1239-1251.
[61] TAN H, YANG K, LI Y, et al. Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation. Immunity. 2017;46(3):488-503.
[62] BAIXAULI F, ACÍN-PÉREZ R, VILLARROYA-BELTRÍ C, et al. Mitochondrial Respiration Controls Lysosomal Function during Inflammatory T Cell Responses. Cell Metab. 2015;22(3):485-498.
[63] ONNIS A, FINETTI F, PATRUSSI L, et al. The small GTPase Rab29 is a common regulator of immune synapse assembly and ciliogenesis. Cell Death Differ. 2015;22(10):1687-1699.
[64] HUTAGALUNG AH, NOVICK PJ. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 2011;91(1):119-149.
[65] IEZZI G, KARJALAINEN K, LANZAVECCHIA A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 1998;8(1):89-95.
[66] LEI T, JIANG Z, WANG J, et al. Genetic Influence of the Brain on Muscle Structure: A Mendelian Randomization Study of Sarcopenia. J Cachexia Sarcopenia Muscle. 2025;16(1):e13647.
[67] RAZOOKY BS, OBERMAYER B, O’MAY JB, et al. Viral Infection Identifies Micropeptides Differentially Regulated in smORF-Containing lncRNAs. Genes (Basel). 2017;8(8):206.
[68] WU Y, WANG H, XIANG W, et al. EDEM2 is a diagnostic and prognostic biomarker and associated with immune infiltration in glioma: A comprehensive analysis. Front Oncol. 2023;12: 1054012.
[69] GHENEA S, CHIRITOIU M, TACUTU R, et al. Targeting EDEM protects against ER stress and improves development and survival in C. elegans. PLoS Genet. 2022;18(2):e1010069.
[70] BA H, WANG Y, ZHANG L, et al. Prediction of Immune Infiltration Diagnostic Gene Biomarkers in Kawasaki Disease. J Immunol Res. 2022;2022:8739498. |